Search

Your search keyword '"Glosli, Heidi"' showing total 164 results
Start Over Author "Glosli, Heidi"
Sorry, I don't understand your search. ×
164 results on '"Glosli, Heidi"'

1. Quantitative diffusion-weighted MRI response assessment in rhabdomyosarcoma: an international retrospective study on behalf of the European paediatric Soft tissue sarcoma Study Group Imaging Committee

Author

van Ewijk, Roelof, Chatziantoniou, Cyrano, Adams, Madeleine, Bertolini, Patrizia, Bisogno, Gianni, Bouhamama, Amine, Caro-Dominguez, Pablo, Charon, Valerie, Coma, Ana, Dandis, Rana, Devalck, Christine, De Donno, Giulia, Ferrari, Andrea, Fiocco, Marta, Gallego, Soledad, Giraudo, Chiara, Glosli, Heidi, ter Horst, Simone A. J., Jenney, Meriel, Klein, Willemijn M., Leemans, Alexander, Leseur, Julie, Mandeville, Henry C., McHugh, Kieran, Merks, Johannes H. M., Minard-Colin, Veronique, Moalla, Salma, Morosi, Carlo, Orbach, Daniel, Ording Muller, Lil-Sofie, Pace, Erika, Di Paolo, Pier Luigi, Perruccio, Katia, Quaglietta, Lucia, Renard, Marleen, van Rijn, Rick R., Ruggiero, Antonio, Sirvent, Sara I., De Luca, Alberto, and Schoot, Reineke A.

Published
2023
Full Text
View/download PDF

2. Outcomes in lung-only metastatic rhabdomyosarcoma: An analysis of data from the European paediatric Soft tissue sarcoma Study Group MTS 2008 study

Author

Chisholm, Julia C., Schoot, Reineke A., Cameron, Alison L., Casanova, Michela, Minard-Colin, Veronique, Coppadoro, Beatrice, Garrido, Marta, Rogers, Timothy, Orbach, Daniel, Glosli, Heidi, Ben-Arush, Miriam, Ferman, Sima, Scarzello, Giovanni, van Rijn, Rick R., Hladun, Raquel, Corradini, Nadege, Ferrari, Andrea, Jenney, Meriel, Bisogno, Gianni, and Merks, Johannes H.M.

Published
2023
Full Text
View/download PDF

4. Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments

Author

Chargari, Cyrus, Haie-Meder, Christine, Espenel, Sophie, Garcia, Max-Adrien, Ben-Arush, Myriam, Bolle, Stéphanie, Borjesson, Anna, Cesen, Maja, Lago, Rita Costa, Defachelles, Anne-Sophie, De Moerloose, Barbara, Devalck, Christine, Edslev, Pernille, Farinha, Nuno Jorge, Francotte, Nadine, Glosli, Heidi, Gouy, Sebastien, Burrieza, Gabriela Guillen, Helfre, Sylvie, Irtan, Sabine, Kattamis, Antonis, Lacerda, Ana, Levy, Antonin, Hjalgrim, Lisa Lyngsie, Mansuy, Ludovic, Mascard, Eric, Moalla, Salma, Orbach, Daniel, Owens, Cormac, Philippe-Chomette, Pascale, Pizer, Barry, Pluchart, Claire, Renard, Marleen, Rognlien, Anne Gro Wesenberg, Rome, Angélique, Sarnacki, Sabine, Safwat, Akmal, Schiavetti, Amalia, Serre, Jill, Verite, Cécile, Weid, Nicolas Von Der, Wysocki, Mariusz, Valteay-Couanet, Dominique, Deutsch, Eric, Minard-Colin, Véronique, Martelli, Hélène, and Guérin, Florent

Published
2022
Full Text
View/download PDF

6. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Author

Nurmeev, Ildar, Safina, Asiya, Zapletal, Ondrej, Brandão, Leonardo R, Kuhn, Tomas, Votava, Tomas, Felgenhauer, Judy, Sharathkumar, Anjali, Svirin, Pavel, Amid, Ali, Halton, Jacqueline, Gorbatikov, Kirill, Saracco, Paola, Kiss, Csongor, Halimeh, Susan, Reschke, Madlen, Wulff, Beate, David, Michele, Novak, Zbynek, Trunina, Inna, Albisetti, Manuela, Frisk, Tony, Glosli, Heidi, Groll, Andreas, Lvova, Olga, Sasmaz, Ilgen, Sosothikul, Darintr, Zilinskaite, Virginija, Cockrell, Erin, Digtyar, Valeriy, Hadacova, Ivana, Palmu, Sauli, Pawar, Anjali, Annichino Bizzacchi, Joyce Maria, Caliskan, Umran, Celkan, Tiraje, Dmytriiev, Dmytro, Druzgal, Colleen Harkins, Onelda Elena, Graciela, Kattamis, Antonis, Kavakli, Ramazan Kaan, Male, Christoph, Ozdemir, Nihal, Van Damme, An, Zvereva, Tatiana, Aarli, Aanen, Paredes Aguilera, Rogelio Alejandro, Aytac, Selin, Carneiro, Jorge, Chistolini, Antonio, Mazzucconi, Maria Gabriela, Corrales-Medina, Fernando, Couturaud, Francis, Croteau, Stacey E, Trenor III, Cameron, Damgaard, Michael, Dixon, Natalia, Galustyan, Anna, Hak, Jiri, Hoffmann, Marianne, Kupesiz, Alphan, Labarque, Veerle, van Geet, Christel, Lin, Ming-Chih, Fu, Yun-Ching, Loggetto, Sandra, Mondelaers, Veerle, Odri-Komazec, Irena, Revel-Vilk, Shoshana, Sevilla, Julian, Fuzzato Silva, Luciano, Kerr Saraiva, José, Montes Tapia, Fernando Felix, Woods-Swafford, Wendy, Luciani, Matteo, Bomgaars, Lisa, Chalmers, Elizabeth, Mitchell, Lesley G, Tartakovsky, Igor, Simetzberger, Monika, Huang, Fenglei, Sun, Zhichao, Kreuzer, Jörg, Gropper, Savion, Reilly, Paul, and Brueckmann, Martina

Published
2021
Full Text
View/download PDF

7. Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B.

Author

Mårtensson, Annika, Letelier, Anna, Manderstedt, Eric, Glosli, Heidi, and Ljung, Rolf

Subjects
HEMOPHILIA, MOSAICISM, POLYMERASE chain reaction, BLOOD coagulation factor IX, FAMILIES
Abstract

Introduction: Of newly diagnosed cases of haemophilia B, the proportion of sporadic cases is usually 50% of severe cases and 25% of moderate/mild cases. However, cases presumed to be sporadic due to family history may not always be sporadic. Few case reports have been published on mosaicism in haemophilia B. Aim: The present study aimed to trace the origin of the pathogenic variant in a well‐defined cohort of sporadic cases of haemophilia B by haplotyping markers. It also aimed to determine the frequency of mosaicism in presumed non‐carrier mothers. Methods: The study group was 40 families, each with a sporadic case of haemophilia B analysed in two‐to‐three generations by Sanger sequencing, haplotyping and using the sensitive droplet digital polymerase chain reaction (ddPCR) technique. Results: In 31/40 (78%) of the families, the mother carried the same pathogenic variant as her son, while Sanger sequencing showed that 9/40 (22%) of the mothers did not carry this variant. Of these variants, 2/9 (22%) were shown to be mosaics by using the ddPCR technique. 16/21 carrier mothers, with samples from three generations available, had a de novo pathogenic variant of which 14 derived from the healthy maternal grandfather. Conclusion: The origin of the pathogenic variant in sporadic cases of haemophilia B is most often found in the X‐chromosome derived from the maternal grandfather or, less often, from the maternal grandmother. Mosaic females seem to be found at the same frequency as in haemophilia A but at a lower percentage of the pathogenic variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry.

Author

van der Zwet, Konrad, de Kovel, Marloes, Motwani, Jayashree, van Geet, Chris, Nolan, Beatrice, Glosli, Heidi, Escuriola Ettingshausen, Carmen, Königs, Christoph, Kenet, Gili, and Fischer, Kathelijn

Subjects
EMICIZUMAB, HEMOPHILIACS, BLOOD coagulation factor VIII antibodies, CHILD patients, HEMORRHAGE, PATIENT safety
Abstract

Introduction: Despite the rapid uptake of emicizumab in the paediatric haemophilia A (HA) population, real‐world data on the safety and efficacy is limited. Aim: To report on bleeding and safety in paediatric patients receiving emicizumab prophylaxis. Methods: Data were extracted from the multicentre prospective observational PedNet Registry (NCT02979119). Children with haemophilia A, and ≥50 FVIII exposures or inhibitors present receiving emicizumab maintenance therapy were analysed. Data were summarized as medians with interquartile range (IQR, P25–P75). Mean (95% confidence interval (CI)), annualized (joint) bleeding rate (A(J)BR) during emicizumab and ≤2 years before emicizumab prophylaxis were modelled and compared using negative binomial regression. Results: Total of 177 patients started emicizumab at median 8.6 years (IQR 4.8–13.1), most had no FVIII inhibitors (64%). Follow up before emicizumab was median: 1.68 years (IQR: 1.24–1.90) and during emicizumab: 1.32 years (IQR:.94–2.11). In patients without inhibitors, mean ABR reduced after starting emicizumab from 2.41 (CI 1.98–2.95) to 1.11 (CI.90–1.36, p <.001), while AJBR reduced from.74 (CI.56–.98) to.31 (CI.21–.46, p <.001). Concordantly, in patients with inhibitors, mean ABR reduced from 5.08 (CI 4.08–6.38) to.75 (CI.56–1.01, p <.001), while AJBR reduced from 1.90 (CI 1.42–2.58) to.34 (CI.21–.56, p <.001). Five emicizumab‐related adverse events were reported (3% of the cohort), including one patient with antidrug antibodies. Conclusion: This study showed improved bleeding control compared to previous treatment and a favourable safety profile during emicizumab therapy in paediatric haemophilia A patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Author

Bisogno, Gianni, De Salvo, Gian Luca, Bergeron, Christophe, Gallego Melcón, Soledad, Merks, Johannes H, Kelsey, Anna, Martelli, Helene, Minard-Colin, Veronique, Orbach, Daniel, Glosli, Heidi, Chisholm, Julia, Casanova, Michela, Zanetti, Ilaria, Devalck, Christine, Ben-Arush, Myriam, Mudry, Peter, Ferman, Sima, Jenney, Meriel, and Ferrari, Andrea

Published
2019
Full Text
View/download PDF

10. Effect of Music Therapy on Parent-Infant Bonding Among Infants Born Preterm

Author

Ghetti, Claire M., primary, Gaden, Tora Söderström, additional, Bieleninik, Łucja, additional, Kvestad, Ingrid, additional, Assmus, Jörg, additional, Stordal, Andreas Størksen, additional, Aristizabal Sanchez, Luisa Fernanda, additional, Arnon, Shmuel, additional, Dulsrud, Jeanette, additional, Elefant, Cochavit, additional, Epstein, Shulamit, additional, Ettenberger, Mark, additional, Glosli, Heidi, additional, Konieczna-Nowak, Ludwika, additional, Lichtensztejn, Marcela, additional, Lindvall, Merethe Wolf, additional, Mangersnes, Julie, additional, Murcia Fernández, Luz Dary, additional, Røed, Catharina Janner, additional, Saá, Gladys, additional, Van Roy, Betty, additional, Vederhus, Bente Johanne, additional, and Gold, Christian, additional

Published
2023
Full Text
View/download PDF

12. Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study

Author

Bisogno, Gianni, primary, Minard-Colin, Veronique, additional, Zanetti, Ilaria, additional, Ferrari, Andrea, additional, Gallego, Soledad, additional, Dávila Fajardo, Raquel, additional, Mandeville, Henry, additional, Kelsey, Anna, additional, Alaggio, Rita, additional, Orbach, Daniel, additional, Terwisscha van Scheltinga, Sheila, additional, Guillén Burrieza, Gabriela, additional, Ben-Arush, Myriam, additional, Glosli, Heidi, additional, Mudry, Peter, additional, Ferman, Sima, additional, Devalck, Christine, additional, Defachelles, Anne Sophie, additional, Merks, Johannes Hendrikus Maria, additional, and Jenney, Meriel, additional

Published
2023
Full Text
View/download PDF

15. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report

Author

Mercolini, Federico, primary, Merks, Johannes H. M., additional, Minard‐Colin, Veronique, additional, Cameron, Alison, additional, van Scheltinga, Scheila E. J. Terwisscha, additional, Sher, Osnat, additional, Fichera, Giulia, additional, Orbach, Daniel, additional, Glosli, Heidi, additional, Coppadoro, Beatrice, additional, Gallego, Soledad, additional, Chisholm, Julia C., additional, and Bisogno, Gianni, additional

Published
2022
Full Text
View/download PDF

17. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study

Author

Ferrari, Andrea, primary, Chisholm, Julia C, additional, Jenney, Meriel, additional, Minard-Colin, Veronique, additional, Orbach, Daniel, additional, Casanova, Michela, additional, Guillen, Gabriela, additional, Glosli, Heidi, additional, van Rijn, Rick R, additional, Schoot, Reineke A, additional, Cameron, Alison L, additional, Rogers, Timothy, additional, Alaggio, Rita, additional, Ben-Arush, Myriam, additional, Mandeville, Henry C, additional, Devalck, Christine, additional, Defachelles, Anne-Sophie, additional, Coppadoro, Beatrice, additional, Bisogno, Gianni, additional, and Merks, Johannes H M, additional

Published
2022
Full Text
View/download PDF

19. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study

Author

Vaarwerk, Bas, van der Lee, Johanna H., Breunis, Willemijn B., Orbach, Daniel, Chisholm, Julia C., Cozic, Nathalie, Jenney, Meriel, van Rijn, Rick R., McHugh, Kieran, Gallego, Soledad, Glosli, Heidi, Devalck, Christine, Gaze, Mark N., Kelsey, Anna, Bergeron, Christophe, Stevens, Michael C. G., Oberlin, Odile, Minard‐Colin, Veronique, and Merks, Johannes H. M.

Published
2018
Full Text
View/download PDF

20. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies

Author

Rogers, Timothy, primary, Zanetti, Ilaria, additional, Coppadoro, Beatrice, additional, Martelli, Hélène, additional, Jenney, Meriel, additional, Minard‐Colin, Veronique, additional, Terwisscha van Scheltinga, Sheila E. J., additional, Skerritt, Clare, additional, Fajardo, Raquel Dávila, additional, Guérin, Florent, additional, Kelsey, Anna, additional, Merks, Johannes H. M., additional, Mandeville, Henry, additional, Guillén, Gabriela, additional, Glosli, Heidi, additional, De Corti, Federica, additional, and Bisogno, Gianni, additional

Published
2022
Full Text
View/download PDF

21. Brachytherapy for pediatric patients at Gustave Roussy Cancer Campus: A model of international cooperation for highly specialized treatments

Author

Chargari, Cyrus Haie-Meder, Christine Espenel, Sophie Garcia, Max-Adrien Ben-Arush, Myriam Bolle, Stéphanie Borjesson, Anna Cesen, Maja Lago, Rita Costa Defachelles, Anne-Sophie De Moerloose, Barbara Devalck, Christine Edslev, Pernille Farinha, Nuno Jorge Francotte, Nadine Glosli, Heidi Gouy, Sebastien Burrieza, Gabriela Guillen Helfre, Sylvie Irtan, Sabine Kattamis, Antonis Lacerda, Ana Levy, Antonin Hjalgrim, Lisa Lyngsie Mansuy, Ludovic Mascard, Eric Moalla, Salma Orbach, Daniel Owens, Cormac Philippe-Chomette, Pascale Pizer, Barry Pluchart, Claire Renard, Marleen Rognlien, Anne Gro Wesenberg Rome, Angélique Sarnacki, Sabine Safwat, Akmal Schiavetti, Amalia Serre, Jill Verite, Cécile Weid, Nicolas Von Der Wysocki, Mariusz Valteay-Couanet, Dominique Deutsch, Eric Minard-Colin, Véronique Martelli, Hélène Guérin, Florent

Abstract

PURPOSE: Childhood cancer is rare, and treatment is frequently associated with long-term morbidity. Disparities in survival and long-term side-effects encourage the establishment of networks to increase access to complex organ conservative strategies, such as brachytherapy (BT). We report our experience of an international cooperation model in childhood cancers. METHODS AND MATERIALS: We examined the outcome of all children referred to our center from national or international networks to be treated according to a multimodal organ-conservative approach including BT. RESULTS: 305 patients were identified; median age at diagnosis was 2.2 years (1.4 months-17.2 years). Ninety-nine (32.4%) were treated within 2015-2020. One hundred seventy-two (56.4%) were referred from national centers and 133 (43.6%) were international patients, from 31 countries (mainly Europe). Two hundred sixty three patients were referred for primary treatment and 42 for salvage treatment. Genito-urinary tumors were the most frequent sites, with 56.4% bladder/prostate rhabdomyosarcoma (RMS) and 28.5% gynecological tumors. In addition to BT, local treatment comprised partial tumor resection in 207 (67.9%) and 39 (13%) had additional external radiotherapy. Median follow-up was 58 months (range: 1 month-48 years), 93 months for national patients and 37 months for international patients (p

Published
2022

23. Localised rhabdomyosarcoma in infants (<12 months) and young children (12–36 months of age) treated on the EpSSG RMS 2005 study

Author

Slater, Olga, primary, Gains, Jennifer E., additional, Kelsey, Anna M., additional, De Corti, Federica, additional, Zanetti, Ilaria, additional, Coppadoro, Beatrice, additional, Jorgensen, Mette, additional, Gallego, Soledad, additional, Orbach, Daniel H., additional, Glosli, Heidi, additional, Cesen, Maja, additional, Gaze, Mark N., additional, Smeulders, Naima, additional, Ferrari, Andrea, additional, Jenney, Meriel, additional, Minard-Colin, Veronique, additional, Bisogno, Gianni, additional, and Merks, Johannes H.M., additional

Published
2022
Full Text
View/download PDF

24. Informed consent and assent guide for paediatric clinical trials in Europe

Author

Lepola, Pirkko, primary, Kindred, Maxine, additional, Giannuzzi, Viviana, additional, Glosli, Heidi, additional, Dehlinger-Kremer, Martine, additional, Dalrymple, Harris, additional, Neubauer, David, additional, Boylan, Geraldine B, additional, Conway, Jean, additional, Dewhurst, Jo, additional, and Hoffman, Diane, additional

Published
2021
Full Text
View/download PDF

25. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) – RMS2005 study

Author

Glosli, Heidi, primary, Bisogno, Gianni, additional, Kelsey, Anna, additional, Chisholm, Julia C., additional, Gaze, Mark, additional, Kolb, Frederic, additional, McHugh, Kieran, additional, Shipley, Janet, additional, Gallego, Soledad, additional, Merks, Johannes H.M., additional, Smeele, Ludi E., additional, Mandeville, Henry, additional, Ferrari, Andrea, additional, Minard-Colin, Veronique, additional, Corradini, Nadege, additional, Jenney, Meriel, additional, Zanetti, Ilaria, additional, De Salvo, Gian L., additional, and Orbach, Daniel, additional

Published
2021
Full Text
View/download PDF

27. Informed consent and assent guide for paediatric clinical trials in Europe.

Author

Lepola, Pirkko, Kindred, Maxine, Giannuzzi, Viviana, Glosli, Heidi, Dehlinger-Kremer, Martine, Dalrymple, Harris, Neubauer, David, Boylan, Geraldine B., Conway, Jean, Dewhurst, Jo, and Hoffman, Diane

Subjects
CLINICAL trials, PEDIATRICS, DECISION making in law, YOUNG adults, INFERTILITY, VOICE disorders, ETHICS, INFORMED consent (Medical law)
Abstract

Objective: Clinical trial sponsors spend considerable resources preparing informed consent (IC) and assent documentation for multinational paediatric clinical trial applications in Europe due to the limited and dispersed patient populations, the variation of national legal and ethical requirements, and the lack of detailed guidance. The aim of this study was to design new easy-to-use guide publicly available on European Medicines Agency's, Enpr-EMA website for all stakeholders.Methods: Current EU legal, ethical and regulatory guidance for paediatric clinical trials were collated, analysed and divided into 30 subject elements in two tables. The European Network of Young Person's Advisory Group reviewed the data and provided specific comments. A three-level recommendation using 'traffic light' symbols was designed for four age groups of children, according to relevance and the requirements.Results: A single guide document includes two tables: (1) general information and (2) trial-specific information. In the age group of 6-9 years old, 92% of the trial-specific subject elements can be or should be included in the IC discussion. Even in the youngest possible age group (2-5 years old children), the number of elements considered was, on average, 52%.Conclusion: The EU Clinical Trial Regulation (2014) does not contain specific requirements exclusively for paediatric clinical trials. This work is the first to extensively collate all the current legal, regulatory and ethical documentation on the IC process, together with input from adolescents. This guide may increase the ethical standards in paediatric clinical trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience

Author

Bergeron, Christophe, primary, Jenney, Meriel, additional, De Corti, Federica, additional, Gallego, Soledad, additional, Merks, Hans, additional, Glosli, Heidi, additional, Ferrari, Andrea, additional, Ranchère-Vince, Dominique, additional, De Salvo, Gian Luca, additional, Zanetti, Ilaria, additional, Chisholm, Julia, additional, Minard-Colin, Véronique, additional, Rogers, Timothy, additional, Bisogno, Gianni, additional, Rose, Adriana, additional, Devalck, Christine, additional, Ferman, Sima, additional, Mudry, Peter, additional, Bergeron, Christophe, additional, Arush, Myriam Weyl Ben, additional, Sejnova, Daniela, additional, Cesen, Maja, additional, and Merks, J. Hans, additional

Published
2021
Full Text
View/download PDF

30. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Author

Halton, Jacqueline, primary, Brandão, Leonardo R, additional, Luciani, Matteo, additional, Bomgaars, Lisa, additional, Chalmers, Elizabeth, additional, Mitchell, Lesley G, additional, Nurmeev, Ildar, additional, Sharathkumar, Anjali, additional, Svirin, Pavel, additional, Gorbatikov, Kirill, additional, Tartakovsky, Igor, additional, Simetzberger, Monika, additional, Huang, Fenglei, additional, Sun, Zhichao, additional, Kreuzer, Jörg, additional, Gropper, Savion, additional, Reilly, Paul, additional, Brueckmann, Martina, additional, Albisetti, Manuela, additional, Safina, Asiya, additional, Zapletal, Ondrej, additional, Kuhn, Tomas, additional, Votava, Tomas, additional, Felgenhauer, Judy, additional, Amid, Ali, additional, Halton, Jacqueline, additional, Saracco, Paola, additional, Kiss, Csongor, additional, Halimeh, Susan, additional, Reschke, Madlen, additional, Wulff, Beate, additional, David, Michele, additional, Novak, Zbynek, additional, Trunina, Inna, additional, Frisk, Tony, additional, Glosli, Heidi, additional, Groll, Andreas, additional, Lvova, Olga, additional, Sasmaz, Ilgen, additional, Sosothikul, Darintr, additional, Zilinskaite, Virginija, additional, Cockrell, Erin, additional, Digtyar, Valeriy, additional, Hadacova, Ivana, additional, Palmu, Sauli, additional, Pawar, Anjali, additional, Annichino Bizzacchi, Joyce Maria, additional, Caliskan, Umran, additional, Celkan, Tiraje, additional, Dmytriiev, Dmytro, additional, Druzgal, Colleen Harkins, additional, Onelda Elena, Graciela, additional, Kattamis, Antonis, additional, Kavakli, Ramazan Kaan, additional, Male, Christoph, additional, Ozdemir, Nihal, additional, Van Damme, An, additional, Zvereva, Tatiana, additional, Aarli, Aanen, additional, Paredes Aguilera, Rogelio Alejandro, additional, Aytac, Selin, additional, Carneiro, Jorge, additional, Chistolini, Antonio, additional, Mazzucconi, Maria Gabriela, additional, Corrales-Medina, Fernando, additional, Couturaud, Francis, additional, Croteau, Stacey E, additional, Trenor III, Cameron, additional, Damgaard, Michael, additional, Dixon, Natalia, additional, Galustyan, Anna, additional, Hak, Jiri, additional, Hoffmann, Marianne, additional, Kupesiz, Alphan, additional, Labarque, Veerle, additional, van Geet, Christel, additional, Lin, Ming-Chih, additional, Fu, Yun-Ching, additional, Loggetto, Sandra, additional, Mondelaers, Veerle, additional, Odri-Komazec, Irena, additional, Revel-Vilk, Shoshana, additional, Sevilla, Julian, additional, Fuzzato Silva, Luciano, additional, Kerr Saraiva, José, additional, Montes Tapia, Fernando Felix, additional, and Woods-Swafford, Wendy, additional

Published
2021
Full Text
View/download PDF

32. Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding

Author

Andersen, Elisabeth, primary, Chollet, Maria Eugenia, additional, Sletten, Marit, additional, Stavik, Benedicte, additional, Myklebust, Christiane Filion, additional, Skarpen, Ellen, additional, Hoff Backe, Paul, additional, Sandset, Per Morten, additional, Glosli, Heidi, additional, Henriksson, Carola, additional, and Iversen, Nina, additional

Published
2020
Full Text
View/download PDF

36. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG‐RMS2005 study

Author

Terwisscha van Scheltinga, Sheila E. J., primary, Wijnen, Marc H. W. A., additional, Martelli, Hélène, additional, Rogers, Timothy, additional, Mandeville, Henry, additional, Gaze, Mark N., additional, McHugh, Keiran, additional, Corradini, Nadege, additional, Orbach, Daniel, additional, Jenney, Meriel, additional, Kelsey, Anna, additional, Chisholm, Julia, additional, Gallego, Soledad, additional, Glosli, Heidi, additional, Ferrari, Andrea, additional, Zanetti, Ilaria, additional, De Salvo, Gian Luca, additional, Minard‐Colin, Veronique, additional, Bisogno, Giani, additional, van Noesel, Max M., additional, and Merks, Hans H. M., additional

Published
2020
Full Text
View/download PDF

40. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Author

Bisogno, Gianni, Jenney, Meriel, Bergeron, Christophe, Gallego Melcón, Soledad, Ferrari, Andrea, Oberlin, Odile, Carli, Modesto, Stevens, Michael, Kelsey, Anna, De Paoli, Angela, Gaze, Mark N, Martelli, Helene, Devalck, Christine, Merks, Johannes H, Ben-Arush, Myriam, Glosli, Heidi, Chisholm, Julia, Orbach, Daniel, Minard-Colin, Veronique, De Salvo, Gian Luca, University of Zurich, and Bisogno, Gianni

Subjects
10036 Medical Clinic, 610 Medicine & health, 2730 Oncology
Published
2018

43. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Author

Bisogno, Gianni, primary, Jenney, Meriel, additional, Bergeron, Christophe, additional, Gallego Melcón, Soledad, additional, Ferrari, Andrea, additional, Oberlin, Odile, additional, Carli, Modesto, additional, Stevens, Michael, additional, Kelsey, Anna, additional, De Paoli, Angela, additional, Gaze, Mark N, additional, Martelli, Helene, additional, Devalck, Christine, additional, Merks, Johannes H, additional, Ben-Arush, Myriam, additional, Glosli, Heidi, additional, Chisholm, Julia, additional, Orbach, Daniel, additional, Minard-Colin, Veronique, additional, De Salvo, Gian Luca, additional, Cesen, Maja, additional, Rose, Adriana, additional, Ferman, Sima, additional, Mudry, Peter, additional, Sejnova, Daniela, additional, Dal Bianco, Paola, additional, Zanetti, Ilaria, additional, Niggli, Felix, additional, Rogers, Timothy, additional, Cecchetto, Giovanni, additional, De Corti, Federica, additional, Guerin, Florent, additional, Terwisscha, Sheila, additional, Ranchere, Dominique, additional, Alaggio, Rita, additional, Shipley, Janet, additional, Rosolen, Angelo, additional, Mandeville, Henry, additional, Scarzello, Giovanni, additional, Bernier, Valerie, additional, and McHugh, Kieran, additional

Published
2018
Full Text
View/download PDF

44. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study

Author

Vaarwerk, Bas, primary, van der Lee, Johanna H., additional, Breunis, Willemijn B., additional, Orbach, Daniel, additional, Chisholm, Julia C., additional, Cozic, Nathalie, additional, Jenney, Meriel, additional, van Rijn, Rick R., additional, McHugh, Kieran, additional, Gallego, Soledad, additional, Glosli, Heidi, additional, Devalck, Christine, additional, Gaze, Mark N., additional, Kelsey, Anna, additional, Bergeron, Christophe, additional, Stevens, Michael C. G., additional, Oberlin, Odile, additional, Minard-Colin, Veronique, additional, and Merks, Johannes H. M., additional

Published
2017
Full Text
View/download PDF

45. Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only:a NOPHO-AML study

Author

Molgaard-Hansen, Lene, Skou, Anne-Sofie, Juul, Anders, Glosli, Heidi, Jahnukainen, Kirsi, Jarfelt, Marianne, Jónmundsson, Guðmundur K, Malmros, Johan, Nysom, Karsten, and Hasle, Henrik

Subjects
Adult, Anti-Mullerian Hormone, Male, Questionnaires, Adolescent, Puberty, Primary Ovarian Insufficiency, humanities, Leukemia, Myeloid, Acute, Young Adult, surgical procedures, operative, Fertility, hemic and lymphatic diseases, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Survivors, Follicle Stimulating Hormone, Child, neoplasms, Follow-Up Studies
Abstract

More than 60% of children with acute myeloid leukemia (AML) become long-term survivors. Most are cured using chemotherapy without hematopoietic stem cell transplantation (HSCT). We report on pubertal development and compare self-reported parenthood among AML survivors and their siblings.

Published
2013

46. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

Author

Gallego, Soledad, Zanetti, Ilaria, Orbach, Daniel, Ranchère, Dominique, Shipley, Janet, Zin, Angelica, Bergeron, Christophe, de Salvo, Gian Luca, Chisholm, Julia, Ferrari, Andrea, Jenney, Meriel, Mandeville, Henry C., Rogers, Timothy, Merks, Johannes H. M., Mudry, Peter, Glosli, Heidi, Milano, Giuseppe Maria, Ferman, Sima, Bisogno, Gianni, and on behalf of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Subjects
ALVEOLAR rhabdomyosarcoma, LYMPH node cancer, CANCER prognosis, CANCER treatment, CANCER patients
Abstract

Background: Alveolar rhabdomyosarcoma (aRMS) with lymph node involvement (N1 classification) accounts for up to 10% of all cases of RMS. The prognosis is poor, and is comparable to that of distant metastatic disease. In the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS2005 protocol, patients with a histologic diagnosis of aRMS/N1 received intensified chemotherapy with systematic locoregional treatment.Methods: Patients with aRMS/N1 were enrolled prospectively after primary surgery/biopsy and fusion status was assessed in tumor samples. All patients received 9 cycles of induction chemotherapy and 6 months of maintenance therapy. Local treatment included radiotherapy to the primary site and lymph nodes with or without secondary surgical resection.Results: A total of 103 patients were enrolled. The clinical characteristics of the patients were predominantly unfavorable: 90% had macroscopic residual disease after initial surgery/biopsy, 63% had locally invasive tumors, 77% had a tumor measuring >5 cm, and 81% had disease at unfavorable sites. Fusion genes involving forkhead box protein O1 (FOXO1) were detected in 56 of 84 patients. Events occurred in 52 patients: 43 developed disease recurrence, 7 had disease that was refractory to treatment, and 2 patients developed second neoplasms. On univariate analysis, unfavorable disease site, tumor invasiveness, Intergroup Rhabdomyosarcoma Study group III, and fusion-positive status correlated with worse prognosis. The 5-year event-free survival rate of patients with fusion-positive tumors was 43% compared with 74% in patients with fusion-negative tumors (P = .01). On multivariate analysis, fusion positivity and tumor invasiveness proved to be unfavorable prognostic markers.Conclusions: Fusion status and tumor invasiveness appear to have a strong impact on prognosis in patients with aRMS/N1. Fusion status will be used to stratify these patients in the next EpSSG RMS study, and treatment will be intensified in patients with fusion-positive tumors. Cancer 2018. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO–AML Study

Author

Wilhelmsson, Mari, Glosli, Heidi, Ifversen, Marianne, Abrahamsson, Jonas, Winiarski, Jacek, Jahnukainen, Kirsi, and Hasle, Henrik

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves event-free survival in acute myeloid leukemia (AML); however, the burden of late effects may be increased. We compared health-related outcomes in childhood AML survivors treated according to the NOPHO-AML protocols either with or without allo-HSCT at age < 21 years. Out of the 147 eligible AML survivors treated with allo-HSCT, 95 (65%) and 53 (75%) of their eligible siblings completed a questionnaire. Their data were compared to corresponding data collected previously from NOPHO-AML survivors treated with chemotherapy only (CT) (n= 101). The median follow-up was 12 (range 2–28) years after allo-HSCT and 47% had received total body irradiation (TBI)-based conditioning. Allo-HSCT survivors reported significantly more physical health limitations (39% vs 7%, p< 0.005), medications for cardiovascular disease (10% vs 1%, p< 0.05) and use of analgesics (32% vs 11%, p< 0.01) than CT survivors. Health problems prevented 16% of the allo-HSCT survivors from attending school or managing a job vs. 3% among CT survivors (p< 0.05). Among 73 allo-HSCT survivors (age ≥ 15 years), seven females reported natural pregnancies and three males reported unassisted conceptions in partners. Survivors of childhood AML treated with allo-HSCT experienced more physical health limitations and used more medications than the survivors treated with chemotherapy only.

Published
2019
Full Text
View/download PDF

48. Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only:a NOPHO-AML study

Author

Molgaard-Hansen, Lene, Glosli, Heidi, Jahnukainen, Kirsi, Jarfelt, Marianne, Jónmundsson, Guðmundur K, Malmros-Svennilson, Johan, Nysom, Karsten, Hasle, Henrik, and Skov Wehner , Peder

Subjects
Adult, Male, Questionnaires, Adolescent, Health Status, Infant, Newborn, Infant, Leukemia, Myeloid, Acute, Young Adult, hemic and lymphatic diseases, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Survivors, Age of Onset, Child, Follow-Up Studies
Abstract

More than 60% of children with acute myeloid leukemia (AML) become long-term survivors, and approximately 50% are cured with chemotherapy only. Limited data exist about their long-term morbidity and social outcomes. The aim of the study was to compare the self-reported use of health care services, health experience, social outcomes, and lifestyle behavior of AML survivors with that of their sibling controls.

Published
2011

49. Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 × 109/l. The NOPHO experience 1984-2014.

Author

Zeller, Bernward, Glosli, Heidi, Forestier, Erik, Ha, Shau ‐ Yin, Jahnukainen, Kirsi, Jónsson, Ólafur G., Lausen, Birgitte, Palle, Josefine, Hasle, Henrik, and Abrahamsson, Jonas

Subjects
*LEUCOCYTOSIS, *ACUTE myeloid leukemia in children, *LEUKOCYTE count, *LEUKAPHERESIS, *CANCER chemotherapy
Abstract

Hyperleucocytosis in paediatric acute myeloid leukaemia ( AML) is associated with increased morbidity and mortality. We studied hyperleucocytosis in 890 patients with AML aged 0-18 years registered in the Nordic Society of Paediatric Haematology and Oncology ( NOPHO) registry, with special focus on very high white blood cell counts ( WBC >200 × 10/l). Eighty-six patients (10%) had WBC 100-199 × 109/l and 57 (6%) had WBC ≥200 × 109/l. Patients with WBC ≥200 × 109/l had a high frequency of t(9;11) and a paucity of trisomy 8. Due to the high frequency of deaths within the first 2 weeks (30% vs. 1% for all others), overall survival in this group was inferior to patients with WBC <200 × 109/l (39% vs. 61%). Main cause of early death was intracranial haemorrhage and leucostasis. Twenty-six per cent of these patients never started antileukaemic protocol therapy. Leukapheresis or exchange transfusion was used in 24% of patients with hyperleucocytosis without impact on survival. Patients with hyperleucocytosis surviving the first week had identical survival as patients with lower WBC. We conclude that death within the first days after diagnosis is the major challenge in patients with high WBC and advocate rapid initiation of intensive chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols.

Author

Ferrari, Andrea, Trama, Annalisa, Paoli, Angela, Bergeron, Christophe, Merks, Johannes H. M., Jenney, Meriel, Orbach, Daniel, Chisholm, Julia C., Gallego, Soledad, Glosli, Heidi, Salvo, Gian Luca, Botta, Laura, Gatta, Gemma, Bisogno, Gianni, De Paoli, Angela, De Salvo, Gian Luca, and RARECAREnet Working Group

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results